



Ali Raza Khaki, MD

Clinical Assistant Professor, Medicine - Oncology

 Curriculum Vitae available Online

CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr Rm CC-2236

Stanford, CA 94305

Tel (650) 736-0519

Fax (650) 736-7379

Bio

BIO

Dr. Khaki is a hematologist/oncologist with board certification in oncology, hematology, and internal medicine. He is also a clinical assistant professor of oncology at Stanford University School of Medicine.

In his clinical practice, he treats patients all forms of genitourinary cancer, including kidney, bladder, prostate, and testicular. With each patient, he is devoted to providing exceptional, humanistic care. As a medical student, he was named to the national Gold Humanism Honor Society. As a resident, he received the Reza Gandjei Humanism Award.

His research interests include novel therapies for genitourinary cancers, with a focus on urothelial cancer outcomes. He also has studied health care utilization and costs for end-of-life care of cancer patients.

Dr. Khaki has earned honors and recognition from the American Association for Cancer Research, American Society of Clinical Oncology, Bladder Cancer Advocacy Network, Conquer Cancer Foundation, and other organizations.

He has authored numerous articles on topics such as immunotherapy for urothelial cancer, management of cancer patients with COVID-19, and utilization of end-of-life care by cancer patients. His work has appeared in publications including JAMA Oncology, Cancer Investigation, Clinical Genitourinary Cancer, the Journal of Urology, and Lancet. In addition, he is an editor for HemOnc.org and theMednet, the physician-only online community where members share clinical questions and answers.

Dr. Khaki is a member of the American Society of Clinical Oncology, American Society of Hematology, Multinational Association of Supportive Care in Cancer, and American Medical Informatics Association. He is on the Measure Steering Group committee and the Trainee and Early Career Council committee of the American Society of Clinical Oncology.

CLINICAL FOCUS

- Oncology

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology

HONORS AND AWARDS

- John Quale Travel Fellowship, Bladder Cancer Advocacy Network (BCAN) (2020)
- San Antonio Breast Cancer Symposium Clinical Scholar Award, San Antonio Breast Cancer Symposium (2020)
- Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology (ASCO) (2019 (ASCO Quality Symposium))
- Reza Gandjei Resident Humanism Award, University of California, San Francisco (2016)

PROFESSIONAL EDUCATION

- Medical Education: University of California San Diego School of Medicine (2013) CA
- Board Certification, American Board of Internal Medicine , Oncology
- Board Certification, American Board of Internal Medicine , Hematology
- Board Certification, American Board of Internal Medicine , Internal Medicine
- Fellowship, University of Washington, Seattle , Hematology/Oncology
- Residency: UCSF Internal Medicine Residency (2016) CA
- M.S., University of Washington School of Public Health , Epidemiology (2020)
- Fellowship: Fred Hutchinson Cancer Research Center (2020) WA

Publications

PUBLICATIONS

- **Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer.** *Urologic oncology*
Khaki, A. R., Shan, Y., Nelson, R. E., Kaul, S., Gore, J. L., Grivas, P., Williams, S. B.
2021
- **Perioperative Immunotherapy in Muscle-invasive Bladder Cancer.** *European urology oncology*
Tripathi, A., Khaki, A. R., Grivas, P.
2021
- **Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy.** *Urologic oncology*
Diamantopoulos, L. N., Sekar, R. R., Holt, S. K., Khaki, A. R., Miller, N. J., Gadzinski, A., Nyame, Y. A., Vakar-Lopez, F., Tretiakova, M. S., Psutka, S. P., Gore, J. L., Lin, D. W., Schade, et al
2021
- **Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study**
Khaki, A., Shah, D. P., Lustberg, M. B., Accordino, M. K., Stover, D. G., Nagaraj, G., Rivera, D. R., Perez, E. A., Tolaney, S. M., Peppercorn, J., Grivas, P., Warner, J. L., Painter, et al
AMER ASSOC CANCER RESEARCH.2021
- **Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis.** *Cancer investigation*
Wagner, M. J., Pollack, S. M., Cranmer, L. D., Thompson, M. J., Maxwell, S. n., Wright, S. n., Khaki, A. R., Madeleine, M. M., Grivas, P. n., Kuderer, N. M., Lyman, G. H., Loggers, E. T.
2021: 1–11
- **Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists.** *Cancer investigation*
Graham, L. S., Sokolova, A. O., Khaki, A. R., Wu, Q. V., Davidson, N. E.
2021; 39 (1): 21–24

- **Loose Regulatory Standards Portend a New Era of Imprecision Oncology.** *Cancer investigation*
Khaki, A. R.
2021: 1–4
- **A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.** *European urology oncology*
Khaki, A. R., Li, A. n., Diamantopoulos, L. N., Miller, N. J., Carril-Ajuria, L. n., Castellano, D. n., De Kouchkovsky, I. n., Koshkin, V. n., Park, J. n., Alva, A. n., Bilen, M. A., Stewart, T. n., Santos, et al
2021
- **Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.** *BJU international*
Esagian, S. M., Khaki, A. R., Diamantopoulos, L. N., Carril-Ajuria, L. n., Castellano, D. n., De Kouchkovsky, I. n., Park, J. J., Alva, A. n., Bilen, M. A., Stewart, T. F., McKay, R. R., Santos, V. S., Agarwal, et al
2021
- **Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study.** *Cancer discovery*
Rivera, D. R., Peters, S., Panagiotou, O. A., Shah, D. P., Kuderer, N. M., Hsu, C., Rubinstein, S. M., Lee, B. J., Choueiri, T. K., de Lima Lopes, G., Grivas, P., Painter, C. A., Rini, et al
2020
- **Sarcomatoid urothelial carcinoma: Oncologic outcomes from a tertiary center and SEER-Medicare data.**
Sekar, R., Diamantopoulos, L., Khaki, A., Vakar-Lopez, F., Tretiakova, M. S., Psutka, S. P., Holt, S. K., Gore, J. L., Schade, G. R., Lin, D. W., Hsieh, A., Lee, J., Yezefski, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Perioperative blood transfusion and postoperative outcomes in patients undergoing radical cystectomy for bladder cancer.**
Diamantopoulos, L., Sekar, R., Khaki, A., Miller, N., Gadzinski, A., Psutka, S. P., Gore, J. L., Schade, G. R., Lin, D. W., Tretiakova, M. S., Vakar-Lopez, F., True, L. D., Hsieh, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Emerging clinical phenotype of bone metastatic urothelial cancer (mUC): Association of early osseous metastases (EOM) and outcomes.**
Nelson, A., Cronk, R., Szabo, A., Lemke, E., Giever, T. A., Burfeind, J. D., Kilari, D., Riese, M., Bylow, K. A., Diamantopoulos, L., Khaki, A., Wright, M., MacLennan, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.** *Lancet (London, England)*
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y. n., Rubinstein, S. M., Rivera, D. R., Shete, S. n., Hsu, C. Y., Desai, A. n., de Lima Lopes, G. n., Grivas, P. n., Painter, C. A., Peters, et al
2020
- **Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes** *BLADDER CANCER*
Diamantopoulos, L. N., Khaki, A., Grivas, P., Gore, J. L., Schade, G. R., Hsieh, A. C., Lee, J. K., Yezefski, T., Yu, E. Y., Schweizer, M. T., Cheng, H. H., Psutka, S. P., Lin, et al
2020; 6 (1): 71–81
- **Use of Real-World Electronic Health Records to Estimate Risk, Risk Factors, and Disparities for COVID-19 in Patients With Cancer.** *JAMA oncology*
Desai, A. n., Khaki, A. R., Kuderer, N. M.
2020
- **Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program.** *Clinical genitourinary cancer*
Diamantopoulos, L. N., Holt, S. K., Khaki, A. R., Sekar, R. R., Gadzinski, A. n., Nyame, Y. A., Vakar-Lopez, F. n., Tretiakova, M. S., Psutka, S. P., Gore, J. L., Lin, D. W., Schade, G. R., Hsieh, et al
2020
- **Comparison of Health Care Utilization at the End of Life Among Patients With Cancer in Alberta, Canada, Versus Washington State.** *JCO oncology practice*
Khaki, A. R., Xu, Y. n., Cheung, W. Y., Li, L. n., Fedorenko, C. n., Grivas, P. n., Ramsey, S. n., Shankaran, V. n.
2020; 16 (12): e1543–e1552

- **Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest.** *Cancer*
Khaki, A. R., Agarwal, N. n., Pal, S. K., Grivas, P. n.
2020; 126 (20): 4446–50
- **Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board.** *Targeted oncology*
Kennedy, L. C., Wong, K. M., Kamat, N. V., Khaki, A. R., Bhatia, S. n., Thompson, J. A., Grivas, P. n.
2020; 15 (4): 541–48
- **Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature.** *Clinical genitourinary cancer*
Diamantopoulos, L. N., Khaki, A. R., Sonpavde, G. P., Venur, V. A., Yu, E. Y., Wright, J. L., Grivas, P. n.
2020; 18 (3): e266–e276
- **Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.** *The Journal of urology*
Miller, N. J., Khaki, A. R., Diamantopoulos, L. N., Bilen, M. A., Santos, V. n., Agarwal, N. n., Morales-Barrera, R. n., Devitt, M. n., Nelson, A. n., Hoimes, C. J., Shreck, E. n., Assi, H. n., Gartrell, et al
2020; 204 (1): 63–70
- **Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.** *Cancer*
Khaki, A. R., Li, A. n., Diamantopoulos, L. N., Bilen, M. A., Santos, V. n., Esther, J. n., Morales-Barrera, R. n., Devitt, M. n., Nelson, A. n., Hoimes, C. J., Shreck, E. n., Assi, H. n., Gartrell, et al
2020; 126 (6): 1208–16
- **Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis** *LANCET GLOBAL HEALTH*
Di Tanna, G., Khaki, A., Theron, G., McCarthy, K., Cox, H., Mupfumi, L., Trajman, A., Zijenah, L., Mason, P., Durovni, R., Bara, W., Hoelscher, M., Clowes, et al
2019; 7 (2): E191–E199
- **Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Khaki, A. R., Gadi, V. K., Prasad, V. n.
2019; 17 (12): 1456–58
- **Association of Renin and Aldosterone With Ethnicity and Blood Pressure: The Multi-Ethnic Study of Atherosclerosis** *AMERICAN JOURNAL OF HYPERTENSION*
Rifkin, D. E., Khaki, A. R., Jenny, N. S., McClelland, R. L., Budoff, M., Watson, K., Ix, J. H., Allison, M. A.
2014; 27 (6): 801–10